Eyal Emmanuel - Evogene Executive Vice President-R&D
| EVGN Stock | ILA 602.20 18.60 3.19% |
President
Dr. Eyal Emmanuel was appointed Executive Vice President Research Development at Evogene Ltd. effective July 6 2014. Dr. Eyal Emmanuel joined Evogene in May 2006 and since that time has held various Research Development management positions at the Company most recently as Vice President RD of the Companys AgChemicals division. Prior to joining Evogene Dr. Emmanuel served as a researcher at Life Science Research Israel Israels premier life sciences research center. Dr. Emmanuel holds a BSc degree from the Hebrew University Faculty of Agriculture and a MSc degree and PhD degree from the Weizmann Institute of Science since 2014.
| Age | 50 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | (972) 8 946 6724 |
| Web | www.evogene.com |
Evogene Management Efficiency
The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | PRESIDENT Age | ||
| Pnina Strauss | Kamada | 40 | |
| Yael Brenner | Kamada | 52 | |
| Zurit Levine | Compugen | 55 | |
| Eitan Kyiet | Kamada | N/A | |
| Eran Schenker | Kamada | 52 | |
| Mark Kapel | Evogene | 47 | |
| Barak Bashari | Kamada | 50 | |
| Ruth Wolfson | Kamada | 68 | |
| Shani Dotan | Kamada | 41 | |
| Ella Sorani | BioLine RX | 55 | |
| Michal Stein | Kamada | N/A | |
| Naveh Tov | Kamada | ||
| Orit Pinchuk | Kamada | 50 | |
| Michal Ayalon | Kamada | N/A | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 |
Evogene Leadership Team
Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Kapel, Executive Vice President-Technology | ||
| Martin Gerstel, Chairman of the Board | ||
| Oded Shoseyov, Director | ||
| Yaron Eldad, Chief Officer | ||
| Eyal Ronen, Exec Devel | ||
| Adina Makover, Independent Director | ||
| Adrian Percy, Director | ||
| Sarit Firon, Independent Director | ||
| Sassi Masliah, Exec Devel | ||
| Liat Wejgman, VP HR | ||
| Eran Kosover, Executive Vice President & General Manager Ag-Chemicals | ||
| Ofer CPA, CEO Pres | ||
| Ofer Haviv, President, Chief Executive Officer | ||
| Ido Dor, Executive Vice President & General Manager Ag-Biologicals | ||
| Dotan Borenstein, Chief Ltd | ||
| Nir Arbel, Chief Officer | ||
| Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals | ||
| Leon Recanati, Independent Director | ||
| Alin SelaBrown, Vice President Screening & Validation Systems | ||
| Kinneret Savitsky, Independent Director | ||
| Eyal Emmanuel, Executive Vice President-R&D | ||
| Arnon Heyman, Vice President & General Manager of Ag-Seeds | ||
| Alex Taskar, Chief Financial Officer | ||
| Ziv Kop, Independent Director | ||
| Elran MBA, Chief Ltd |
Evogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 3.37 % | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.